Atherosclerotic Cardiovascular Disease: key endpoint results by drug

The key endpoints of Atherosclerotic Cardiovascular Disease trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Atherosclerotic Cardiovascular Disease page.

LDL-C, % change

LDL-C, % change in Atherosclerotic Cardiovascular Disease: 22 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Alirocumab-52.7%-0.3%−52.4300 mg Q4W/Up 150 mg Q2W · wk 24 · n 144NCT01926782 Phase 3, primary
Bempedoic acid-22.6%-1.2%−21.4wk 12 · n 224NCT02988115 Phase 3, primary
Bempedoic acid/ezetimibe-36.2%1.8%−38180 mg + 10 mg FDC · wk 12 · n 86NCT03337308 Phase 3, primary
Berberine ursodeoxycholate (HTD1801)-9.8%-3.6%−6.21000 mg BID · wk 4 · n 12NCT03381287 Phase 1/2, secondary
Colestilan-27.5%2.8%−30.215 g · wk 12 · n 99NCT00542386 Phase 3, primary
Enlicitide-58.2%2.6%−60.8wk 24 · n 198NCT05952869 Phase 3, primary
Evolocumab-50.1%6.8%−57wk 52 · n 599NCT01516879 Phase 3, primary
Ezetimibe-27.7%-0.9%−26.7wk 12 · n 85NCT00867165 Phase 3, primary
Ezetimibe/simvastatin (Vytorin)-49.3%-38.0% (Atorvastatin)—10/20 mg · wk 8 · n 124NCT00496730 Phase 3, primary
Hyzetimibe-16.4%a-6.8% (atorvastatin alone)—wk 12NCT03433196 Phase 3, primary
Icosapent Ethyl1.5%8.8%−7.34 g/day · wk 12 · n 225NCT01047501 Phase 3, secondary
Inclisiran-49.3%4.2%−53.5wk 72.9 · n 810NCT03400800 Phase 3, primary
Laroprovstat-46.6%4.1%−50.730 mg · wk 12 · n 85NCT06173570 Phase 2, primary
Lerodalcibep-9.3%a-11% (evolocumab)—wk 24NCT04034485 Phase 3, primary
Obicetrapib-29.9%2.7%−32.610mg · wk 12 · n 1679NCT05142722 Phase 3, primary
Olpasiran-16.7%6.2%−23225 mg Q12W · wk 36 · n 54NCT04270760 Phase 2, secondary
Pelacarsen-16%-1%−1560 mg Q4W · n 47NCT03070782 Phase 2, secondary
Pemafibrate31.5%2.3%+29.2wk 12 · n 311NCT03011450 Phase 3, secondary
Recaticimab-51%a2%−53450mg Q12W · wk 24NCT04885218 Phase 3, primary
Resmetirom-10.6%8.2%−18.8wk 12 · n 76NCT03038022 Phase 2, primary
Rosuvastatin-38.5%-0.5%−385 mg · wk 12 · n 42NCT00355615 Phase 3, primary
Tafolecimab-58.7%a3.2%−61.9tafolecimab 450mg Q4W · wk 12NCT04179669 Phase 3, primary

Drugs checked with no result here: 26 not reported, 21 trial running, 15 not posted.

Non-HDL-C, % change

Non-HDL-C, % change in Atherosclerotic Cardiovascular Disease: 13 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Alirocumab-53.7%0.9%−54.6150 mg Q2W · wk 12 · n 1530NCT01507831 Phase 3, secondary
Bempedoic acid-11.9%1.5%−13.4wk 12 · n 1488NCT02666664 Phase 3, secondary
Bempedoic acid/ezetimibe-31.9%1.8%−33.7180 mg + 10 mg FDC · wk 12 · n 86NCT03337308 Phase 3, secondary
Enlicitide-52.3%2.1%−54.4wk 24 · n 198NCT05952869 Phase 3, secondary
Evolocumab-41.8%8.4%−50.3wk 52 · n 599NCT01516879 Phase 3, secondary
Ezetimibe-55.6%-51%−4.6wk 12 · n 262NCT00639158 Phase 3, secondary
Icosapent Ethyl-5%9.8%−14.84 g/day · wk 12 · n 226NCT01047501 Phase 3, secondary
Inclisiran-41.2%2.1%−43.3wk 72.9 · n 810NCT03400800 Phase 3, secondary
Laroprovstat-41.6%3.5%−45.230 mg · wk 12 · n 85NCT06173570 Phase 2, secondary
Obicetrapib-26.6%2.8%−29.410mg · wk 12 · n 1685NCT05142722 Phase 3, secondary
Pemafibrate-21.0%-3.4%−17.5wk 12 · n 311NCT03011450 Phase 3, secondary
Resmetirom-12%7.5%−19.5wk 12 · n 76NCT03038022 Phase 2, secondary
Rosuvastatin-36.3%-0.8%−35.55 mg · wk 12 · n 42NCT00355615 Phase 3, secondary

Drugs checked with no result here: 27 not reported, 22 trial running, 22 not posted.

ApoB, % change

ApoB, % change in Atherosclerotic Cardiovascular Disease: 17 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Alirocumab-55.5%0.5%−56150 mg Q2W · wk 12 · n 1468NCT01507831 Phase 3, secondary
Bempedoic acid-8.6%3.3%−11.9wk 12 · n 1485NCT02666664 Phase 3, secondary
Bempedoic acid/ezetimibe-24.6%5.5%−30.1180 mg + 10 mg FDC · wk 12 · n 82NCT03337308 Phase 3, secondary
Enlicitide-48.2%1.8%−50wk 24 · n 197NCT05952869 Phase 3, secondary
Evolocumab-41.3%2.9%−44.2wk 52 · n 599NCT01516879 Phase 3, secondary
Ezetimibe-49.1%-44.7%−4.4wk 12 · n 248NCT00639158 Phase 3, secondary
Icosapent Ethyl-2.2%7.1%−9.34 g/day · wk 12 · n 217NCT01047501 Phase 3, secondary
Inclisiran-38.1%0.8%−38.9wk 72.9 · n 810NCT03400800 Phase 3, secondary
Laroprovstat-37.0%2.9%−39.930 mg · wk 12 · n 85NCT06173570 Phase 2, secondary
Lepodisiran-13.9%0.2%−14.1400 mg · wk 8.57 · n 69NCT05565742 Phase 2, secondary
Muvalaplin-17.6%-1.7%−15.9240 mg · wk 12 · n 57NCT05563246 Phase 2, secondary
Obicetrapib-17.8%1.1%−18.910mg · wk 12 · n 1685NCT05142722 Phase 3, secondary
Olpasiran-10.2%7.4%−17.6225 mg Q12W · wk 36 · n 54NCT04270760 Phase 2, secondary
Pelacarsen-8%1%−960 mg Q4W · n 47NCT03070782 Phase 2, secondary
Pemafibrate0.6%-1.7%+2.2wk 12 · n 311NCT03011450 Phase 3, secondary
Resmetirom-14.2%3.8%−18wk 12 · n 76NCT03038022 Phase 2, secondary
Rosuvastatin-32.1%-1.5%−30.65 mg · wk 12 · n 42NCT00355615 Phase 3, secondary

Drugs checked with no result here: 27 not reported, 19 trial running, 21 not posted.

Lp(a), % change

Lp(a), % change in Atherosclerotic Cardiovascular Disease: 14 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Alirocumab-28.2%-3.1%−25.1150 mg Q2W · wk 12 · n 1530NCT01507831 Phase 3, secondary
Bempedoic acid16.2%-2.7%+18.9120 mg · wk 12 · n 38NCT01262638 Phase 2, secondary
Berberine ursodeoxycholate (HTD1801)-21.9%10.6%−32.51000 mg BID · wk 4 · n 12NCT03381287 Phase 1/2, secondary
Enlicitide-24.7%-1.6%−23.1wk 24 · n 196NCT05952869 Phase 3, secondary
Evolocumab-27.7%-5.4%−22.3wk 52 · n 599NCT01516879 Phase 3, secondary
Inclisiran-4.6%4.3%−8.9wk 12.86 · n 37NCT03851705 Phase 3, secondary
Laroprovstat-19.4%0%−19.430 mg · wk 12 · n 76NCT06173570 Phase 2, secondary
Lepodisiran-74.4%3.1%−77.596 mg · n 74NCT05565742 Phase 2, primary
Muvalaplin-85.7%0.5%−86.2240 mg · wk 12 · n 47NCT05563246 Phase 2, primary
Obicetrapib-0.5%13.7%−14.110mg · wk 12 · n 1685NCT05142722 Phase 3, secondary
Olpasiran-97.5%3.6%−101.1225 mg Q12W · wk 36 · n 53NCT04270760 Phase 2, primary
Pelacarsen-72%-6%−6660 mg Q4W · n 47NCT03070782 Phase 2, primary
Resmetirom-21.8%4.4%−26.2wk 12 · n 76NCT03038022 Phase 2, secondary
Rosuvastatin-20.7%3.5% (Rosuvastatin)—75 mg/up to 150 mg + 10 mg · wk 12 · n 48NCT01730053 Phase 3, secondary

Drugs checked with no result here: 26 not reported, 20 trial running, 24 not posted.

3-point MACE (% with event)

3-point MACE (% with event) in Atherosclerotic Cardiovascular Disease: 3 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Evolocumab7.9%9.9%−2wk 156 · n 13784NCT01764633 Phase 3, secondary
Icosapent Ethyl11.2%14.8%−3.6n 4089NCT01492361 Phase 3, secondary
Liraglutide (Victoza)13%14.9%−1.9wk 260 · n 4668NCT01179048 Phase 3, primary

Drugs checked with no result here: 27 not reported, 25 trial running, 29 not posted.

  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 84 approved or late-stage drugs with a featured trial in Atherosclerotic Cardiovascular Disease were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.